Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
Sharma A, Wu J, Ezekowitz JA, Felker GM, Udell JA, Heidenreich PA, Fonarow GC, Mahaffey KW, Hernandez AF, DeVore AD.
Sharma A, et al.
ESC Heart Fail. 2020 Feb;7(1):274-278. doi: 10.1002/ehf2.12528. Epub 2019 Nov 20.
ESC Heart Fail. 2020.
PMID: 31747132
Free PMC article.
Clinical Trial.
AIMS: Sodium-glucose co-transporter (SGLT)-2 inhibitors have been shown to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (DM) and high cardiovascular …
AIMS: Sodium-glucose co-transporter (SGLT)-2 inhibitors have been shown to reduce the risk of cardiovascular death and …